LONDON (Alliance News) - Oxford Biomedica PLC said Monday it had completed patient recruitment for its Phase I trial of neovascular wet age-related macular degeneration treatment RetinoStat. The condition is age related, and causes blindness and visual impairment. The company said tha Read More